Bahrain vs Barbados: Statin use vs. average non-HDL cholesterol levels
Bahrain
3.3
in 2018
Barbados
3.3
in 2018
Bahrain rank
95th
Barbados rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Bahrain
- Barbados
How they compare
Bahrain currently reports 3.3 against 3.3 in Barbados, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Bahrain ahead.
Bahrain ranks 95th and Barbados ranks 95th of 191 countries.
Bahrain has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bahrain | Barbados | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.9 | 3.2 | 0.7 | Bahrain |
| 1990s | 3.87 | 3.16 | 0.71 | Bahrain |
| 2000s | 3.7 | 3.18 | 0.52 | Bahrain |
| 2010s | 3.43 | 3.26 | 0.1778 | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Bahrain or Barbados?
- Bahrain, at 3.3 against 3.3 in Barbados as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Bahrain and Barbados?
- 0, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Barbados?
- 39 years are reported by both, from 1980 to 2018.
- How do Bahrain and Barbados rank globally for statin use vs. average non-hdl cholesterol levels?
- Bahrain ranks 95th and Barbados ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.